LipocineSTU:2VT0 50 PS Ratio is 14.09 as of Jul. 04, 2026, which is 78% below its 10-year median of 62.63. GuruFocus rates STU:2VT0 with a GF Score™ of 50/100 and a GF Value™ of €3.10. The stock has 4 warning signs investors should review. Among 933 Biotechnology companies, Lipocine ranks better than 57.45% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lipocine's share price is €3.944.
Lipocine's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.28. Hence, Lipocine's PS Ratio for today is 14.09.
The historical rank and industry rank for Lipocine's PS Ratio or its related term are showing as below:
STU:2VT0'
s PS Ratio Range Over the Past 10 Years
Min: 1.5 Med: 62.63 Max: 1839.09
Current: 7.35
During the past 13 years, Lipocine's highest PS Ratio was 1839.09. The lowest was 1.50. And the median was 62.63.
STU:2VT0's PS Ratio is ranked better than 57.45% of 933
companies
in the Biotechnology industry
Industry Median: 9.64
vs STU:2VT0: 7.35
Lipocine Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Lipocine was -49.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 53.90% per year.
During the past 13 years, Lipocine's highest 3-Year average Revenue per Share Growth Rate was 109.40% per year. The lowest was -13.00% per year. And the median was 24.85% per year.
Back to Basics: PS Ratio
Lipocine (STU:2VT0) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Lipocine PS Ratio Related Terms
Lipocine PS Ratio Historical Data
* Premium members only.
The historical data trend for Lipocine's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lipocine's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipocine PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipocine's PS Ratio distribution charts can be found below:
* The bar in red indicates where Lipocine's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Lipocine's Share Price of today is €3.944. Lipocine's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.28.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lipocine (STU:2VT0) has a PS Ratio of 14.09 as of Jul. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lipocine and its competitors. This is 78% below median its historical median of 62.63. Over the past decade, Lipocine's PS Ratio has ranged from 1.50 to 1,839.09. According to the industry distribution chart, Lipocine ranks #397 out of 933 companies in the Biotechnology industry, placing it in the top 42.6%.
Is Lipocine's PS Ratio too high?
Lipocine's current PS Ratio of 14.09 is 78% below median its 10-year median of 62.63. Over the past 10 years, this metric has ranged from a low of 1.50 to a high of 1,839.09. The Biotechnology industry median PS Ratio is 9.64. Lipocine's value of 14.09 is 46.2% above this industry median. Based on the distribution chart, Lipocine ranks #397 out of 933 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lipocine has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Lipocine's PS Ratio compare to NCEL and PTN?
According to the Biotechnology industry distribution chart, Lipocine ranks #397 out of 933 companies for PS Ratio. This puts Lipocine in the upper half of its industry. The industry median PS Ratio is 9.64. Lipocine's value of 14.09 is 46.2% above this benchmark. Historically, Lipocine's own PS Ratio has ranged from 1.50 to 1,839.09 over the past decade. While the company's 10-year median is 62.63 vs. the industry median of 9.64, Lipocine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lipocine's current PS Ratio of 14.09 is 46.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lipocine and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lipocine's current PS Ratio is 14.09, which is 78% below median its own 10-year median of 62.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipocine stock overvalued right now?
Lipocine (STU:2VT0) has a current PS Ratio of 14.09. The stock's GF Value™ is €3.10, compared to a current price of €3.94 — trading 27.2% above its estimated fair value. The current PS Ratio is 14.09, which is 78% below median its 10-year median of 62.63 and 46.2% above the Biotechnology industry median of 9.64. Lipocine's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Lipocine (STU:2VT0), the current PS Ratio is 14.09 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lipocine (STU:2VT0) Overvalued in 2026?
Based on GuruFocus' analysis, Lipocine stock appears to be overvalued.
The current stock price of €3.94 is trading 27.2% above its estimated GF Value™ of €3.10.
Key valuation signals for STU:2VT0:
PS Ratio: 14.09 (78% below median its 10-year median of 62.63)
GF Value™: €3.10 vs. price of €3.94 (27.2% above fair value)
Industry Position: 46.2% above the Biotechnology median (#397 of 933)
No single metric tells the full story. See the STU:2VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
50GF Score
Get the complete analysis for STU:2VT0
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2VT0 has been successfully added to your 
